Emerging Role of MYB Transcription Factors in Cancer Drug Resistance

Overview

Journal Cancer Drug Resist

Date 2024 Jun 5

PMID 38835346

Authors

Bernhard Biersack

Michael Hopfner

Affiliations

Soon will be listed here.

Abstract

Decades ago, the viral myeloblastosis oncogene - was identified as a gene responsible for the development of avian leukemia. However, the relevance of MYB proteins for human cancer diseases, in particular for solid tumors, remained basically unrecognized for a very long time. The human family of MYB transcription factors comprises MYB (c-MYB), MYBL2 (b-MYB), and MYBL1 (a-MYB), which are overexpressed in several cancers and are associated with cancer progression and resistance to anticancer drugs. In addition to overexpression, the presence of activated MYB-fusion proteins as tumor drivers was described in certain cancers. The identification of anticancer drug resistance mediated by MYB proteins and their underlying mechanisms are of great importance in understanding failures of current therapies and establishing new and more efficient therapy regimens. In addition, new drug candidates targeting MYB transcription factor activity and signaling have emerged as a promising class of potential anticancer therapeutics that could tackle MYB-dependent drug-resistant cancers in a more selective way. This review describes the correlation of MYB transcription factors with the formation and persistence of cancer resistance to various approved and investigational anticancer drugs.

Citing Articles

Targeting histone acetylation to overcome drug resistance in the parasite .

Seifert-Gorzycki J, Munoz D, Lizarraga A, Iriarte L, Coceres V, Strobl-Mazzulla P bioRxiv. 2025; .

PMID: 39829914 PMC: 11741363. DOI: 10.1101/2025.01.07.631743.

References

Lotz C, Lamour V . The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance. Cancer Drug Resist. 2022; 3(2):149-160. PMC: 9090595. DOI: 10.20517/cdr.2019.114. View

Vrana J, DECKER R, Johnson C, Wang Z, Jarvis W, Richon V . Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene. 1999; 18(50):7016-25. DOI: 10.1038/sj.onc.1203176. View

Ladu S, Calvisi D, Conner E, Farina M, Factor V, Thorgeirsson S . E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology. 2008; 135(4):1322-32. PMC: 2614075. DOI: 10.1053/j.gastro.2008.07.012. View

Kfir-Erenfeld S, Haggiag N, Biton M, Stepensky P, Assayag-Asherie N, Yefenof E . miR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis. Oncotarget. 2016; 8(1):472-489. PMC: 5352135. DOI: 10.18632/oncotarget.13447. View

Zhang X, Li Y, Ma H, Gao Y . Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis. Sci Rep. 2020; 10(1):6893. PMC: 7181810. DOI: 10.1038/s41598-020-63396-8. View

Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H . Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem Cells. 2003; 21(3):315-21. DOI: 10.1634/stemcells.21-3-315. View

Liu F, Wang Y, Cao Y, Wu Z, Ma D, Cai J . Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer. Chem Biol Interact. 2023; 374:110412. DOI: 10.1016/j.cbi.2023.110412. View

Sottile F, Gnemmi I, Cantilena S, DAcunto W, Sala A . A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Oncotarget. 2012; 3(5):535-45. PMC: 3388183. DOI: 10.18632/oncotarget.498. View

Smarda J, Zemanova K, Bryja J, Smardova J, Kozubik A, Hofmanova J . Retinoid X receptor suppresses transformation by the v-myb oncogene. J Leukoc Biol. 1999; 66(6):1039-48. DOI: 10.1002/jlb.66.6.1039. View

10.

Guan X, Meng X, Zhu K, Kai J, Liu Y, Ma Q . MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3-phospho-BAD pathway. Cell Death Discov. 2022; 8(1):84. PMC: 8881619. DOI: 10.1038/s41420-022-00881-1. View

11.

Andersson M, Aman P, Stenman G . IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors. Cells. 2019; 8(8). PMC: 6721700. DOI: 10.3390/cells8080913. View

12.

Okumura F, Uematsu K, Byrne S, Hirano M, Joo-Okumura A, Nishikimi A . Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α. Mol Cell Biol. 2016; 36(12):1803-17. PMC: 4907096. DOI: 10.1128/MCB.00067-16. View

13.

Calvo E, Soria J, Ma W, Wang T, Bahleda R, Tolcher A . A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clin Cancer Res. 2016; 23(5):1177-1185. DOI: 10.1158/1078-0432.CCR-15-2301. View

14.

Lim S, Damnernsawad A, Shyamsunder P, Chng W, Han B, Xu L . Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations. Haematologica. 2019; 104(6):1209-1220. PMC: 6545861. DOI: 10.3324/haematol.2018.201483. View

15.

Mahmood U, Bang A, Chen Y, Mak R, Lorch J, Hanna G . A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2020; 109(1):134-144. PMC: 9361179. DOI: 10.1016/j.ijrobp.2020.08.018. View

16.

Srivastava S, Bhardwaj A, Singh S, Arora S, McClellan S, Grizzle W . Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis. 2012; 33(6):1149-57. PMC: 3514863. DOI: 10.1093/carcin/bgs134. View

17.

Albert V, Piendl G, Yousseff D, Lammert H, Hummel M, Ortmann O . Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects. Arch Gynecol Obstet. 2022; 306(4):1197-1210. PMC: 9470618. DOI: 10.1007/s00404-022-06434-2. View

18.

Kohler L, Reich S, Yusenko M, Klempnauer K, Shaikh A, Ahmed K . A New Naphthopyran Derivative Combines -Myb Inhibition, Microtubule-Targeting Effects, and Antiangiogenic Properties. ACS Med Chem Lett. 2022; 13(11):1783-1790. PMC: 9661705. DOI: 10.1021/acsmedchemlett.2c00403. View

19.

Benes P, Maceckova V, Zatloukalova J, Kovarova L, Smardova J, Smarda J . Retinoic acid enhances differentiation of v-myb-transformed monoblasts induced by okadaic acid. Leuk Res. 2007; 31(10):1421-31. DOI: 10.1016/j.leukres.2007.03.005. View

20.

Sun B, Wang Y, Sun J, Zhang C, Xia R, Xu S . Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid. Am J Cancer Res. 2021; 11(3):773-792. PMC: 7994170. View